BenevolentAI Investor Day Presentation Deck
Internal Pipeline - continued progress
BEN-2293 | Atopic Dermatitis
BEN-8744 | Ulcerative Colitis
BEN-9160 | Amyotrophic Lateral Sclerosis
BEN-28010 | Glioblastoma Multiforme
Inflammatory Bowel Disease
Amyotrophic Lateral Sclerosis
Antiviral
Oncology
Oncology
Nonalcoholic Steatohepatitis
Oncology
Parkinson's Disease
Parkinson's Disease
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
10+ Exploratory stage programmes
Target ID
Hit to Lead Lead Opt
AstraZeneca
AstraZeneca
AstraZeneca
Preclinical
Phase I
Phase II Phase III
Progress in 1H22 - several programmes have
progressed through key DD stage gates
GBM - Candidate nominated,
IND-enabling studies to begin
2nd ALS asset - transitioned through to
Candidate Seeking
2 oncology programmes - transitioned
into Lead Optimisation
New portfolio entrant for Parkinson's
Disease
Benevolent 62View entire presentation